Need professional-grade analysis? Visit stockanalysis.com
$114.55B
36.78
1,571
N/A
Concord Biotech Limited (CONCORDBIO) trades on NSE in INR. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at INR1081.70, up 4.27% from the previous close.
Over the past year, CONCORDBIO has traded between a low of INR1014.80 and a high of INR2116.90. The stock has lost 35.2% over this period. It is currently 48.9% below its 52-week high.
Concord Biotech Limited has a market capitalization of $114.55B, with a price-to-earnings ratio of 36.78.
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Side-by-side comparison against top Healthcare peers.